Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
On Monday, Alector, Inc. ALEC released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD).
Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.53 per share a year ago.
Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript
Alector, Inc. (NASDAQ:ALEC ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Katie Hogan – Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal – Co-Founder and Chief Executive Officer Sara Kenkare-Mitra – President and Head-Research and Development Gary Romano – Chief Medical Officer Marc Grasso – Chief Financial Officer Conference Call Participants Michael Reid – Morgan Stanley Carter Gould – Barclays Tom Shrader – BTIG Sarah Schram – William Blair & Company Ananda Ghosh – H.C. Wainwright & Company Graig Suvannavejh – Mizuho Securities Corinne Jenkins – Goldman Sachs Operator Good afternoon, ladies and gentlemen, and welcome to the Alector Second Quarter and Midyear 2024 Earnings Conference Call.
Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to earnings of $0.02 per share a year ago.
